WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology. At the WCLC conference, " Oncology Frontier" invited Dr. Han Baohui, Zhong Runbo, Zhang Wei, and Lu Jun from the affiliated Thoracic Hospital of Shanghai Jiao Tong University School of Medicine to engage in discussions on hot topics at the conference and important clinical research.
WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

The 2023 World Lung Cancer Congress (WCLC) took place at the Singapore Expo Center from September 9th to 12th. Dr. Shi Meiqi from Jiangsu Cancer Hospital presented crucial findings in a phase 1/2 clinical study at this conference (MA15.09). In an interview with " Oncology Frontier ," Dr. Shi Meiqi shared research insights, key results, and treatment strategies for KRAS mutation non-small cell lung cancer patients.
WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening

WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo. On the first day, Dr. Chen Haiquan, Director of the Lung Cancer Research Center at Fudan University and Chief of Thoracic Surgery at Fudan University Affiliated Tumor Hospital, gave an important presentation. During an interview with "Oncology Frontier", Dr. Chen Haiquan shared the key points of his presentation.
WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam's research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA's approval of a third-generation EGFR inhibitor for metastatic non-small cell lung cancer. Additionally He also led clinical and translational research on new immunotherapies for treating lung cancer , resulting in over 400 published, peer-reviewed publications. He also served on the IASLC board of directors (2017-2021) and the NCI Thoracic Malignancy Steering Committee (2012-2021). He is currently the chief editor of the journal 《Cancer》 published by the American Society of Clinical Oncology.
WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.
WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University's Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the privilege to interview Dr. Johnson during the conference. Here are the highlights:
Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

For the first time in three years, Chinese experts were able to participated in the WCLC conference in person, following the end of the impact of the COVID-19 pandemic , engaging in face-to-face discussions with international scholars. Dr. Wu Yilong, Dr. Cheng Ying, and Dr. Han Baohui shared their experiences of attending the conference in Singapore.